Caroline J Loew: We’re excited to launch Mural Oncology

Caroline J Loew, CEO of Mural Oncology, shared Mural Oncology’s post on LinkedIn adding:

“We’re excited to launch Mural Oncology today! Mural is a clinical stage immuno-oncology company committed to delivering the next generation of IO treatments to patients, starting with our lead asset, nemvaleukin that is in two registrational studies.
We’re looking forward to sharing our story and data as we reach key milestones, both on nemvaleukin and our preclinical pipeline. Stay tuned!
Want to learn more about Mural? Go to this page.”